Ocugen Announces Completion of Dosing in Second Cohort of Phase 1/2 Trial for Stargardt Disease Gene Therapy’
By ’
MALVERN, Pa. May 15, 2024’ ’ Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company dedicated to pioneering advances in gene and cell therapies as well as vaccines, has announced the completion of dosing in the second cohort of its ongoing Phase 1/2 GARDian clinical trial. This trial is evaluating the efficacy and safety of OCU410ST (AAV-hRORA), a modifier gene therapy candidate intended as a one-time treatment for Stargardt disease.
Stargardt disease, a hereditary condition causing progressive vision loss due to the degeneration of the macula, currently has no approved treatments. OCU410ST aims to address this unmet medical need by delivering a modified gene’AAV-hRORA’to target cells in the eye, potentially halting or even reversing disease progression.
The GARDian trial is structured in phases to assess the therapy’s safety and efficacy across different dosages. With the completion of dosing in the second cohort, Ocugen moves one step closer to potentially providing a groundbreaking therapy for patients suffering from Stargardt disease.
Dr. Name, Chief Medical Officer of Ocugen, expressed optimism about the progress, stating, The completion of dosing in the second cohort marks a significant milestone in our journey to develop a much-needed treatment for Stargardt disease. We are encouraged by the trial’s progress and look forward to analyzing the data to determine the next steps.
Ocugen’s commitment to innovative genetic solutions is evident in its robust pipeline, which includes various programs targeting not only rare genetic disorders but also broad applications in gene therapy. The success of OCU410ST could pave the way for advancements in treating other ocular genetic conditions.
The company has not yet disclosed specific data results from the second cohort but plans to release detailed findings after the conclusion of the study. As the GARDian trial advances, stakeholders, including researchers, investors, and patients, eagerly await further developments.
Ocugen’s latest update underscores its dedication to transforming the treatment landscape for rare diseases through cutting-edge biotechnological research.
Comments